Welcome to the e-CCO Library!

OP002: Epigenetic biomarkers to detect ulcerative colitis-associated neoplasia: results from phase I of the ENDCAP-C study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Iqbal T.*1, Beggs A.1, Taniere P.2, Wallis Y.3, Mehta S.4, Magill L.4, Deeks J.4, Matthews G.1, Morton D.1 EndCAP-C Consortium

Created: Wednesday, 20 February 2019, 10:36 AM
OP002: Histopathological response and remission after dual topical application of the Toll-like receptor 9 agonist DIMS0150 in patients with moderate-to-severe ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

R. Atreya*1, A. Öst2, C. Admyre3, A. Karlsson3, T. Knittel3, J. Kowalski3, F. Scaldaferi4, M. Neurath1, C. Hawkey5

Created: Friday, 22 February 2019, 9:49 AM
OP003: Increased risk of acute arterial events in young patients with severely active Inflammatory Bowel Disease: A nationwide French cohort study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kirchgesner J.
Last Modified: Wednesday, 15 March 2017, 1:43 PM by ECCO Administrator
Thromboembolism, Other extraintestinal manifestations
Files: 1
OP003: Increased risk of acute arterial events in young patients with severely active inflammatory bowel disease: a nationwide French cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kirchgesner J.*1,2, Beaugerie L.1, Carrat F.3,4, Nyboe Andersen N.5, Jess T.5,6, Schwarzinger M.7,8 For the BERENICE Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
OP003: Predicting short and medium-term efficacy of the biosimilar infliximab: trough levels/do anti-drug antibodys or clinical/biochemical markers play a more important role?
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

P. A. Golovics*1, Z. Vegh1, M. Rutka2, K. Gecse1, A. Balint2, K. Farkas2, J. Banai3, L. Bene4, B. Gasztonyi5, T. Kristof6, L. Lakatos7, P. Miheller8, K. Palatka9, A. Patai10, A. Salamon11, T. Szamosi3, Z. Szepes12, G.T. Toth13, A. Vincze14, E. Biro15, B. Lovasz1, Z. Kurti1, F. Nagy12, T. Molnar2, P. Lakatos1

Created: Friday, 22 February 2019, 9:49 AM
OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics
Year: 2018
Source: ECCO'18 Vienna
Authors: de Bruyn Magali
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP003: Temporal changes in immune pathways with consecutive biological therapies as measured by serum proteomics
Year: 2018
Source: ECCO '18 Vienna
Authors:

M. de Bruyn1,2*, V. Ballet3, S. Verstockt4, B. Verstockt1,3, G. Van Assche1,3, M. Ferrante1,3, K. Machiels1, S. Vermeire1,3

Created: Thursday, 21 February 2019, 9:14 AM
OP004: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohns disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Stojmirovic*, R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman

Created: Friday, 22 February 2019, 9:49 AM
OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Le Bourhis L.1, Corraliza A.2, Auzolle C.1, Ricart E.2, Hawkey C.3, Lindsay J.O.4, Clark M.3, Rogler G.5, Satsangui J.6, Haller D.7, Panes J.2, Salas A.2, Allez M.*1

Created: Wednesday, 20 February 2019, 10:36 AM
OP004: Resetting of the mucosal T cell repertoire after hematopoietic stem cell transplantation in refractory Crohn‘s Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Allez M.
Last Modified: Wednesday, 15 March 2017, 1:48 PM by ECCO Administrator
Autologous stem cell transplantation, T cell
Files: 1
OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in Ulcerative Colitis
Year: 2018
Source: ECCO'18 Vienna
Authors: García-Olmo, Damian
Created: Friday, 9 November 2018, 10:21 AM by Lindley Fritze
Ulcerative colitis , Genetics , Lymphocyte, T cell
OP004: The TLR9 agonist cobitolimod induces anti-inflammatory effects and balances the Th17/T-reg cell response in ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Schmitt1*, U. Billmeier1, J. Ulmschneider1, C. Admyre2, T. Knittel2, A. Zargari2, M.F. Neurath1, R. Atreya1

Created: Thursday, 21 February 2019, 9:14 AM
OP005: A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

T. Billiet*1, I. Cleynen1, M. Ferrante2, G. Van Assche2, A. Gils3, S. Vermeire2

Created: Friday, 22 February 2019, 9:49 AM
OP005: Apremilast for active ulcerative colitis: a phase 2, randomised, double-blind, placebo-controlled induction study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Danese1*, M. Neurath2, A. Kopon3, S. Zakko4, T. Simmons5, R. Fogel6, J. Maccarone7, X. Zhan7, K. Usiskin7, D. Chitkara7

Created: Thursday, 21 February 2019, 9:14 AM
OP005: The PROSIT cohort of infliximab biosimilar in IBD: A prolonged follow-up on the efficacy and safety across Italy
Year: 2017
Source: ECCO'17 Barcelona
Authors: Fiorino G.
Last Modified: Wednesday, 15 March 2017, 1:53 PM by ECCO Administrator
Anti drug antibodies, Anti-TNF agents, Infliximab, Biosimilars
Files: 1
OP005: The PROSIT cohort of infliximab biosimilar in IBD: a prolonged follow-up on the efficacy and safety across Italy
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Guidi L.1, Fiorino G.*2, Variola A.3, Manetti N.4, Fries W.5, Rizzuto G.6, Bossa F.7, Cappello M.8, Biancone L.9, D'Incà R.10, Cantoro L.11, Castiglione F.12, Principi M.13, Annunziata M.L.14, Di Girolamo M.15, Terpin M.M.16, Cortelezzi C.C.17, Costa F.18, Amato A.19, Di Sabatino A.20, Saibeni S.21, Meucci G.22, Petruzzellis C.23, Tari R.24, Gugliemi F.W.25, Armuzzi A.26, Danese S.2, Geccherle A.3, Rogai F.4, Ventra A.5, Orlando A.6, Andriulli A.7, Scrivo B.8, Troncone E.9, Caccaro R.10, Kohn A.11, Nardone O.12, Annese V.27

Created: Wednesday, 20 February 2019, 10:36 AM
OP006: Apremilast for active Ulcerative Colitis: A phase 2, randomised, double-blind, placebo-controlled induction study
Year: 2018
Source: ECCO'18 Vienna
Authors: Danese Silvio
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP006: Autophagy regulates dendritic cell migration through Rac1: implications for thiopurine therapy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Wildenberg*1, P. Koelink2, K. Diederen2, A. te Velde2, V. Nuij3, M. Peppelenbosch3, M. Nobis4, O. Sansom4, C.J. van der Woude3, G. D’Haens1, G. van den Brink1

Created: Friday, 22 February 2019, 9:49 AM
OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: Long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial
Year: 2017
Source: ECCO'17 Barcelona
Authors: Pouillon L.
Last Modified: Wednesday, 15 March 2017, 1:55 PM by ECCO Administrator
Chron's disease, Ulcerative colitis, Anti TNF drug levels, Anti drug antibodies, Infliximab
Files: 1
OP006: Correlation of durability of response, serum trough concentrations and outcome parameters: long-term follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) trial
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Pouillon L.*1, Ferrante M.1, Van Assche G.1, Rutgeerts P.1, Noman M.1, Vande Casteele N.2, Gils A.3, Vermeire S.1

Created: Wednesday, 20 February 2019, 10:36 AM